Compare AU
Compare DRUG vs. AEBD
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the BetaShares Ethical Australian Composite Bond ETF (AEBD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | AEBD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 1 |
Median incremental investment | $920.50 | $5,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $5,006.43 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | AEBD | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | AEBD.AX was created on 2024-11-04 by BetaShares. The fund's investment portfolio concentrates primarily on broad credit fixed income. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Bloomberg Australian Enhanced Yield Ethically Screened Composite Bond Index, before taking into account fees and expenses. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | MANITOBA (PROVINCE OF) 4.85% AUG-34 (3.65 %) EUROPEAN INVESTMENT BANK 1.9% FEB-36 (3.44 %) INTER-AMERICAN DEVEL BK 1.0% AUG-28 (3.31 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.57 % | 0 % |
Key Summary
DRUG | AEBD | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Bloomberg Australian Enhanced Yield Composite Bond Index - Benchmark TR Gross |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0 % |
Price | $7.95 | $50.57 |
Size | $185.172 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 0.05 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 05/11/2024 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | AEBD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 1 |
Median incremental investment | $920.50 | $5,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $5,006.43 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | AEBD | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | AEBD |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |